Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA)

Marta Ugarte; Marie Brown; Katherine A Hollywood; Garth J Cooper; Paul N Bishop; Warwick B Dunn

doi:10.1186/gm334

Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA)

Marta Ugarte, Marie Brown, Katherine A Hollywood, Garth J Cooper, Paul N Bishop, Warwick B Dunn

Biosciences

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

The prevalence, and associated healthcare burden, of diabetes mellitus is increasing worldwide. Mortality and morbidity are associated with diabetic complications in multiple organs and tissues, including the eye, kidney and cardiovascular system, and new therapeutics to treat these complications are required urgently. Triethylenetetramine (TETA) is one such experimental therapeutic that acts to chelate excess copper (II) in diabetic tissues and reduce oxidative stress and cellular damage.

Original language	English
Pages (from-to)	35
Journal	Genome medicine
Volume	4
Issue number	4
DOIs	https://doi.org/10.1186/gm334
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/gm334

Cite this

@article{1fa12fa7a7fd4100a247537e620a520a,

title = "Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA)",

abstract = "The prevalence, and associated healthcare burden, of diabetes mellitus is increasing worldwide. Mortality and morbidity are associated with diabetic complications in multiple organs and tissues, including the eye, kidney and cardiovascular system, and new therapeutics to treat these complications are required urgently. Triethylenetetramine (TETA) is one such experimental therapeutic that acts to chelate excess copper (II) in diabetic tissues and reduce oxidative stress and cellular damage.",

author = "Marta Ugarte and Marie Brown and Hollywood, {Katherine A} and Cooper, {Garth J} and Bishop, {Paul N} and Dunn, {Warwick B}",

year = "2012",

doi = "10.1186/gm334",

language = "English",

volume = "4",

pages = "35",

journal = "Genome medicine",

issn = "1756-994X",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA)

AU - Ugarte, Marta

AU - Brown, Marie

AU - Hollywood, Katherine A

AU - Cooper, Garth J

AU - Bishop, Paul N

AU - Dunn, Warwick B

PY - 2012

Y1 - 2012

N2 - The prevalence, and associated healthcare burden, of diabetes mellitus is increasing worldwide. Mortality and morbidity are associated with diabetic complications in multiple organs and tissues, including the eye, kidney and cardiovascular system, and new therapeutics to treat these complications are required urgently. Triethylenetetramine (TETA) is one such experimental therapeutic that acts to chelate excess copper (II) in diabetic tissues and reduce oxidative stress and cellular damage.

AB - The prevalence, and associated healthcare burden, of diabetes mellitus is increasing worldwide. Mortality and morbidity are associated with diabetic complications in multiple organs and tissues, including the eye, kidney and cardiovascular system, and new therapeutics to treat these complications are required urgently. Triethylenetetramine (TETA) is one such experimental therapeutic that acts to chelate excess copper (II) in diabetic tissues and reduce oxidative stress and cellular damage.

U2 - 10.1186/gm334

DO - 10.1186/gm334

M3 - Article

C2 - 22546713

SN - 1756-994X

VL - 4

SP - 35

JO - Genome medicine

JF - Genome medicine

IS - 4

ER -

Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA)

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this